|
1
|
Doble BW and Woodgett JR: GSK-3: Tricks of
the trade for a multi-tasking kinase. J Cell Sci. 116:1175–1186.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jope RS and Johnson GV: The glamour and
gloom of glycogen synthase kinase-3. Trends Biochem Sci. 29:95–102.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Grimes CA and Jope RS: The multifaceted
roles of glycogen synthase kinase 3β in cellular signaling. Prog
Neurobiol. 65:391–426. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Beurel E and Jope RS: The paradoxical pro-
and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic
apoptosis signaling pathways. Prog Neurobiol. 79:173–189. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Patel S and Woodgett J: Glycogen synthase
kinase-3 and cancer: Good cop, bad cop? Cancer Cell. 14:351–353.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thiel A, Heinonen M, Rintahaka J,
Hallikainen T, Hemmes A, Dixon DA, Haglund C and Ristimäki A:
Expression of cyclo-oxygenase-2 is regulated by glycogen synthase
kinase-3beta in gastric cancer cells. J Biol Chem. 281:4564–4569.
2006. View Article : Google Scholar
|
|
7
|
Tsuchiya K, Nakamura T, Okamoto R, Kanai T
and Watanabe M: Reciprocal targeting of Hath1 and beta-catenin by
Wnt glycogen synthase kinase 3beta in human colon cancer.
Gastroenterology. 132:208–220. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hu Y, Gu X, Li R, Luo Q and Xu Y: Glycogen
synthase kinase-3β inhibition induces nuclear factor-κB-mediated
apoptosis in pediatric acute lymphocyte leukemia cells. J Exp Clin
Cancer Res. 29:1542010. View Article : Google Scholar
|
|
9
|
Wang Z, Smith KS, Murphy M, Piloto O,
Somervaille TC and Cleary ML: Glycogen synthase kinase 3 in MLL
leukaemia maintenance and targeted therapy. Nature. 455:1205–1209.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zheng CY, Xiao W, Zhu MX, Pan XJ, Yang ZH
and Zhou SY: Inhibition of cyclooxygenase-2 by tetramethylpyrazine
and its effects on A549 cell invasion and metastasis. Int J Oncol.
40:2029–2037. 2012.PubMed/NCBI
|
|
11
|
Chen L, Lu Y, Wu JM, et al: Ligustrazine
inhibits B16F10 melanoma metastasis and suppresses angiogenesis
induced by vascular endothelial growth factor. Biochem Biophys Res
Commun. 386:374–379. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yi B, Liu D, He M, Li Q, Liu T and Shao J:
Role of the ROS/AMPK signaling pathway in
tetramethylpyrazine-induced apoptosis in gastric cancer cells.
Oncol Lett. 6:583–589. 2013.PubMed/NCBI
|
|
13
|
Wu Y, Xu Y, Shen Y, Wang C, Guo G and Hu
T: Tetramethylpyrazine potentiates arsenic trioxide activity
against HL-60 cell lines. Braz J Med Biol Res. 45:187–196. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Apostolidou E, Swords R, Alvarado Y and
Giles FJ: Treatment of acute lymphoblastic leukaemia: A new era.
Drugs. 67:2153–2171. 2007. View Article : Google Scholar
|
|
15
|
Naito S, Bilim V, Yuuki K, Ugolkov A,
Motoyama T, Nagaoka A, Kato T and Tomita Y: Glycogen synthase
kinase-3beta: A prognostic marker and a potential therapeutic
target in human bladder cancer. Clin Cancer Res. 16:5124–5132.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cohen P and Goedert M: GSK3 inhibitors:
Development and therapeutic potential. Nat Rev Drug Discov.
3:479–487. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Alonso M and Martinez A: GSK-3 inhibitors:
Discoveries and developments. Curr Med Chem. 11:755–763. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li WM, Liu HTHT, Li XY, Wu JY, Xu G, Teng
YZ, Ding ST and Yu C: The effect of tetramethylpyrazine on hydrogen
peroxide-induced oxidative damage in human umbilical vein
endothelial cells. Basic Clin Pharmacol Toxicol. 106:45–52.
2010.
|
|
19
|
Deng L, Guo X, Zhai L, Song Y, Chen H,
Zhan P, Wu J and Liu X: Ligustrazine derivatives. Part 4: Design,
synthesis, and biological evaluation of novel ligustrazine-based
stilbene derivatives as potential cardiovascular agents. Chem Biol
Drug Des. 79:731–739. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yin J, Yu C, Yang Z, He JL, Chen WJ, Liu
HZ, Li WM, Liu HT and Wang YX: Tetramethylpyrazine inhibits
migration of SKOV3 human ovarian carcinoma cells and decreases the
expression of interleukin-8 via the ERK1/2, p38 and AP-1 signaling
pathways. Oncol Rep. 26:671–679. 2011.PubMed/NCBI
|
|
21
|
Kawazoe H, Bilim VN, Ugolkov AV, Yuuki K,
Naito S, Nagaoka A, Kato T and Tomita Y: GSK-3 inhibition in vitro
and in vivo enhances antitumor effect of sorafenib in renal cell
carcinoma (RCC). Biochem Biophys Res Commun. 423:490–495. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thamilselvan V, Menon M and Thamilselvan
S: Anticancer efficacy of deguelin in human prostate cancer cells
targeting glycogen synthase kinase-3 β/β-catenin pathway. Int J
Cancer. 129:2916–2927. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
McCubrey JA, Steelman LS, Bertrand FE, et
al: GSK-3 as potential target for therapeutic intervention in
cancer. Oncotarget. 5:2881–2911. 2014.PubMed/NCBI
|
|
24
|
Karin M: Nuclear factor-kappaB in cancer
development and progression. Nature. 441:431–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Aggarwal BB: Nuclear factor-kappaB: The
enemy within. Cancer Cell. 6:203–208. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Weston VJ, Austen B, Wei W, Marston E,
Alvi A, Lawson S, Darbyshire PJ, Griffiths M, Hill F, Mann JR, Moss
PA, Taylor AM and Stankovic T: Apoptotic resistance to ionizing
radiation in pediatric B-precursor acute lymphoblastic leukemia
frequently involves increased NF-kappaB survival pathway signaling.
Blood. 104:1465–1473. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kotliarova S, Pastorino S, Kovell LC, et
al: Glycogen synthase kinase-3 inhibition induces glioma cell death
through c-MYC, nuclear factor-kappaB, and glucose regulation.
Cancer Res. 68:6643–6651. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ougolkov AV, Bone ND, Fernandez-Zapico ME,
Kay NE and Billadeau DD: Inhibition of glycogen synthase kinase-3
activity leads to epigenetic silencing of nuclear factor kappaB
target genes and induction of apoptosis in chronic lymphocytic
leukemia B cells. Blood. 110:735–742. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hatakeyama S, Watanabe M, Fujii Y and
Nakayama KI: Targeted destruction of c-Myc by an engineered
ubiquitin ligase suppresses cell transformation and tumor
formation. Cancer Res. 65:7874–7879. 2005.PubMed/NCBI
|
|
30
|
Tomita N: BCL2 and MYC dual-hit
lymphoma/leukemia. J Clin Exp Hematop. 51:7–12. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tapia JC, Bolanos-Garcia VM, Sayed M,
Allende CC and Allende JE: Cell cycle regulatory protein
p27KIP1 is a substrate and interacts with the protein
kinase CK2. J Cell Biochem. 91:865–879. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Porter LA, Kong-Beltran M and Donoghue DJ:
Spy1 interacts with p27Kip1 to allow G1/S
progression. Mol Biol Cell. 14:3664–3674. 2003. View Article : Google Scholar : PubMed/NCBI
|
